Intelligent Bio Solutions Expands Global Reach with Latin American Spanish Language Integration into Drug Screening System
Intelligent Bio Solutions (NASDAQ: INBS) has announced the integration of Latin American Spanish into its Intelligent Fingerprinting Drug Screening System, expanding its multilingual capabilities alongside English and Arabic. This strategic enhancement targets the growing Latin American drug screening market, projected to reach $1.1 billion by 2030.
The update significantly extends the system's accessibility across Spanish-speaking regions, particularly important as Spanish is the fourth most spoken language globally with over 500 million speakers and official status in more than 20 countries. The expansion is part of a broader multilingual upgrade aimed at reaching over 4 billion potential users worldwide.
The company currently serves over 400 accounts across 19 countries and is preparing to enter the U.S. market following its FDA 510(k) submission in December 2024. In Europe, Spain's drug testing market is expected to reach $368.4 million by 2030.
Intelligent Bio Solutions (NASDAQ: INBS) ha annunciato l'integrazione dello spagnolo latinoamericano nel suo Sistema di Screening Droghe Intelligent Fingerprinting, ampliando così le sue capacità multilingue insieme all'inglese e all'arabo. Questo miglioramento strategico è rivolto al crescente mercato latinoamericano dello screening delle droghe, previsto raggiungere 1,1 miliardi di dollari entro il 2030.
L'aggiornamento amplia significativamente l'accessibilità del sistema nelle regioni di lingua spagnola, un aspetto particolarmente importante dato che lo spagnolo è la quarta lingua più parlata al mondo con oltre 500 milioni di parlanti e status ufficiale in più di 20 paesi. Questa espansione fa parte di un più ampio aggiornamento multilingue pensato per raggiungere oltre 4 miliardi di potenziali utenti a livello globale.
Attualmente l'azienda serve oltre 400 clienti in 19 paesi e si sta preparando ad entrare nel mercato statunitense dopo la presentazione alla FDA 510(k) prevista per dicembre 2024. In Europa, il mercato spagnolo dei test antidroga è stimato raggiungere 368,4 milioni di dollari entro il 2030.
Intelligent Bio Solutions (NASDAQ: INBS) ha anunciado la integración del español latinoamericano en su Sistema de Detección de Drogas Intelligent Fingerprinting, ampliando sus capacidades multilingües junto con el inglés y el árabe. Esta mejora estratégica apunta al creciente mercado latinoamericano de detección de drogas, con una proyección de 1.100 millones de dólares para 2030.
La actualización amplía significativamente la accesibilidad del sistema en regiones de habla hispana, algo especialmente relevante ya que el español es el cuarto idioma más hablado del mundo con más de 500 millones de hablantes y estatus oficial en más de 20 países. Esta expansión forma parte de una actualización multilingüe más amplia destinada a alcanzar a más de 4.000 millones de usuarios potenciales en todo el mundo.
Actualmente, la empresa atiende a más de 400 cuentas en 19 países y se está preparando para ingresar al mercado estadounidense tras su presentación FDA 510(k) en diciembre de 2024. En Europa, se espera que el mercado de pruebas de drogas en España alcance los 368,4 millones de dólares para 2030.
Intelligent Bio Solutions (NASDAQ: INBS)는 라틴 아메리카 스페인어를 Intelligent Fingerprinting 약물 검사 시스템에 통합했다고 발표하며, 영어와 아랍어에 이어 다국어 지원 범위를 확장했습니다. 이 전략적 개선은 2030년까지 11억 달러에 이를 것으로 예상되는 성장 중인 라틴 아메리카 약물 검사 시장을 겨냥합니다.
이번 업데이트로 스페인어권 지역에서 시스템 접근성이 크게 향상되었으며, 스페인어는 전 세계에서 네 번째로 많이 사용되는 언어로 5억 명 이상의 사용자가 있고 20개 이상의 국가에서 공식 언어로 지정되어 있어 매우 중요합니다. 이 확장은 전 세계 40억 명 이상의 잠재 사용자에게 도달하기 위한 광범위한 다국어 업그레이드의 일환입니다.
회사는 현재 19개국에서 400개 이상의 계정을 보유하고 있으며, 2024년 12월 FDA 510(k) 제출 후 미국 시장 진출을 준비 중입니다. 유럽에서는 스페인 약물 검사 시장이 2030년까지 3억 6,840만 달러에 이를 것으로 예상됩니다.
Intelligent Bio Solutions (NASDAQ : INBS) a annoncé l’intégration de l’espagnol latino-américain dans son système de dépistage des drogues Intelligent Fingerprinting, élargissant ainsi ses capacités multilingues aux côtés de l’anglais et de l’arabe. Cette amélioration stratégique vise le marché latino-américain du dépistage des drogues, en pleine croissance, qui devrait atteindre 1,1 milliard de dollars d’ici 2030.
Cette mise à jour améliore considérablement l’accessibilité du système dans les régions hispanophones, ce qui est particulièrement important puisque l’espagnol est la quatrième langue la plus parlée au monde avec plus de 500 millions de locuteurs et un statut officiel dans plus de 20 pays. Cette expansion s’inscrit dans une mise à niveau multilingue plus large visant à toucher plus de 4 milliards d’utilisateurs potentiels dans le monde.
L’entreprise compte actuellement plus de 400 clients dans 19 pays et se prépare à entrer sur le marché américain suite à son dépôt FDA 510(k) prévu en décembre 2024. En Europe, le marché espagnol des tests de dépistage des drogues devrait atteindre 368,4 millions de dollars d’ici 2030.
Intelligent Bio Solutions (NASDAQ: INBS) hat die Integration von lateinamerikanischem Spanisch in sein Intelligent Fingerprinting Drogen-Screening-System bekanntgegeben und erweitert damit seine mehrsprachigen Fähigkeiten neben Englisch und Arabisch. Diese strategische Erweiterung zielt auf den wachsenden lateinamerikanischen Drogenscreening-Markt ab, der bis 2030 voraussichtlich 1,1 Milliarden US-Dollar erreichen wird.
Das Update erhöht die Zugänglichkeit des Systems in spanischsprachigen Regionen erheblich, was besonders wichtig ist, da Spanisch mit über 500 Millionen Sprechern die viertmeistgesprochene Sprache weltweit ist und in mehr als 20 Ländern offiziellen Status besitzt. Die Erweiterung ist Teil eines umfassenderen mehrsprachigen Upgrades, das über 4 Milliarden potenzielle Nutzer weltweit erreichen soll.
Das Unternehmen betreut derzeit über 400 Kunden in 19 Ländern und bereitet den Eintritt in den US-Markt vor, nachdem im Dezember 2024 die FDA 510(k)-Einreichung erfolgt ist. In Europa wird der spanische Drogentestmarkt bis 2030 voraussichtlich 368,4 Millionen US-Dollar erreichen.
- Expansion into Latin American market with projected $1.1B market size by 2030
- Strong existing presence with 400+ accounts across 19 countries
- Pending FDA 510(k) submission for U.S. market entry
- Strategic language expansion targeting 4 billion potential users globally
- FDA approval still pending and not guaranteed
- Faces competition in established markets like Spain
Company expands Intelligent Fingerprinting Drug Screening System multilingual capabilities to meet growing demand across Latin American Spanish-speaking markets
Latin American drug screening market projected to reach USD 1.1 billion by 2030
Expansion is part of major multilingual Drug Screening System upgrade, targeting over 4 billion potential users worldwide
NEW YORK, April 22, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the integration of Latin American Spanish into its Intelligent Fingerprinting Drug Screening System (the “System”). The enhancement allows users to operate the System in English, Arabic, and Latin American Spanish, extending the platform’s usability across diverse, international settings.
Spanish is the fourth most spoken language in the world and the second most spoken language in the U.S. It is the official language in over 20 countries, including the majority of countries in Latin America, and is spoken by over 500 million people globally1. By incorporating Latin American Spanish into the System, INBS strengthens its support for Spanish-speaking markets and regional distribution partners. This update increases accessibility for end-users across North America, Central America, South America, and Europe, aligning with the Company’s strategic growth plans.
“As we see increased interest from Spanish-speaking distributors and companies, we must ensure our solution remains accessible and relevant to these markets. Integrating Latin American Spanish into our System is a key step toward opening new opportunities for future growth,” said Harry Simeonidis, President & CEO at Intelligent Bio Solutions. “As demand grows, so does the value of business localization. Our product stands out in the market by offering local language capabilities, something most solutions don’t provide. It’s a clear differentiator.”
The Latin American drug screening market is projected to reach USD 1.1 billion by 2030, driven by increasing public safety initiatives and growing demand for workplace compliance programs2. In Europe, Spain’s drug testing market is expected to reach USD 368.4 million by 20303, reflecting similar trends in regulation and adoption. INBS’ multilingual capabilities position the Company to better serve evolving testing needs through an intuitive, localized platform experience.
This development forms part of the Company’s major multilingual system upgrade announced earlier this year. The complete multilingual upgrade will support multiple languages spoken across the Americas, Europe, Asia Pacific and the Middle East, making the System accessible to over 4 billion speakers worldwide4. The added capability supports a broader growth strategy to expand on a foundation of over 400 accounts across 19 countries and to penetrate new markets and regions. The Latin American Spanish enhancement is a key development milestone as the Company prepares to enter the multi-billion-dollar U.S. market this year, following its FDA 510(k) submission in December 2024.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.
For more information, visit: http://www.ibs.inc/
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact:
Intelligent Bio Solutions Inc.
info@ibs.inc
LinkedIn | Twitter
Investor & Media Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com
_____________________________
Hyperlinks and website references in this release are provided for convenience only, and do not incorporate the referenced content into this release.
1 Statista 2025. Countries with the largest number of native Spanish speakers worldwide in 2024. Available at: https://www.statista.com/statistics/991020/number-native-spanish-speakers-country-worldwide/
2 Grand View Research 2025. Latin America Drug Screening Market Size & Outlook. Available at: https://www.grandviewresearch.com/horizon/outlook/drug-screening-market/latin-america
3 Grand View Research 2025. Spain Drug Screening Market Size & Outlook, 2018-2030. Available at: https://www.grandviewresearch.com/horizon/outlook/drug-screening-market/spain
4 Ethnologue, 2024. The Ethnologue 200. Available at: https://www.ethnologue.com/insights/ethnologue200/
FAQ
What is the projected market size for drug screening in Latin America by 2030?
How many accounts does INBS currently serve globally?
When did INBS submit its FDA 510(k) application for the U.S. market?
What languages does the INBS Intelligent Fingerprinting Drug Screening System support?
